Cheelcare Inc (CHER) Q4 2026 earnings summary

Executive summary

• Fiscal 2026 revenue grew 22% year-over-year to $1.9 million, driven by increased Companion unit sales and expanded distribution.

• Achieved U.S. Medicare and Medicaid reimbursement eligibility for Companion, supporting broader market access.

• Initiated commercial production and first deliveries of Curio, a robotic complex-rehab power wheelchair.

• Transitioned to a new 16,000 sq. ft. production facility and strengthened finance and reporting infrastructure.

Financial highlights

• Fiscal 2026 revenue: $1,908,941, up 22% from $1,569,887 in fiscal 2025.

• Gross profit: $464,525 (24% margin), down from $663,963 (42%) due to a $443,000 inventory write-off and labor cost reclassification.

• Net loss: $4,859,475 ($0.27/share), compared to $1,270,041 ($0.12/share) in fiscal 2025, impacted by listing expense, derivative loss, and debt settlement.

• Q4 2026 revenue: $628,407, up 78% year-over-year; Q4 net loss: $2,172,093, reflecting continued investment and one-time charges.

Outlook and guidance

• Focus on building Companion sales, improving manufacturing efficiency and margins, and advancing Curio's regulatory and commercial progress.

• Management remains committed to Curio's long-term potential despite extended regulatory timelines.